Stella Xu
Board Of Directors @ ARMO BioSciences
Stella Xu is a Series B investor at ARMO BioSciences focused on Biotechnology and Health Care. Stella Xu, Ph.D. has served as a member of our board of directors since November 2018. Dr. Xu has served as Managing Director of Quan Capital, a life sciences venture fund with offices in China and the United States, since August 2017. Prior to joining Quan Capital, Dr. Xu served as Vice President and site head of Roche Innovation Center Shanghai,and a member of the global management team for Roche’s Immunology, Inflammation & Infectious Diseases Discovery and Translation Area, from September 2012 to August 2017. Dr. Xu joined Roche from McKinsey & Company. Dr. Xu has served as a director of Centrexion Therapeutics Corporation, a biopharmaceutical company focused on the treatment of chronic pain, since January 2018 and previously served as a director of ARMO BioSciences, Inc., a late-stage biopharmaceutical company focused on immuno-oncology, from August 2017 to July 2018 when it was acquired by Eli Lilly and Company. Dr. Xu received a B.S. in biophysics from Peking University and a Ph.D. in immunology from Northwestern University.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Stella Xu invests in
Stages Stella Xu invests in
Countries Stella Xu invests in
Investment Focus
Industry
- Biotechnology 6 (86%)
- Health Care 4 (57%)
- Life Science 2 (29%)
- Medical 1 (14%)
- Biopharma 1 (14%)
Stage
- Series B 3 (43%)
- Series A 2 (29%)
- Series C 1 (14%)
- Series D 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Walking Fish Therapeutics
|
Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies. | $50M / Series A / Sep 13, 2021 | |
Design Therapeutics
|
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases. | $125M / Series B / Jan 27, 2021 | |
|
Design Therapeutics
|
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases. | $45.5M / Series A / Mar 20, 2020 | |
NextCure
|
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products. | $93M / Series B / Nov 13, 2018 | |
Tempest Therapeutics
|
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response.Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California. | $70M / Series B / Mar 28, 2018 | |
Centrexion Therapeutics
|
Centrexion Therapeutics is focused on developing new therapies for moderate to severe chronic pain that address the safety and efficacy gaps in the current treatment paradigm.We aim to relieve the suffering associated with chronic pain by creating treatments that address the safety and efficacy gaps in the current treatment paradigm. | $67M / Series D / Jan 02, 2018 | |
ARMO BioSciences
|
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California. | $67M / Series C / Aug 29, 2017 |
Co-Investors
ArrowMark Partners
2 deals together
SR One
2 deals together
Surveyor Capital
2 deals together
WestRiver Group
2 deals together
Bay City Capital
1 deal together
Canaan Partners
1 deal together
About ARMO BioSciences
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.
ARMO BioSciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Stella Xu
Board Of Directors
|
|||
Peter Van Vlasselaer
CEO
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Stella Xu invest in?
Stella Xu invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Stella Xu last invest?
The most recent investment recorded for Stella Xu closed in Sep 2021. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
